ORIGINAL RESEARCH published: 10 July 2020 doi: 10.3389/fphar.2020.01043 A Bromodomain-Containing Protein 4 (BRD4) Inhibitor Suppresses Angiogenesis by Regulating AP-1 Expression † † Zijun Zhou 1 , Xiaoming Li 4 , Zhiqing Liu 3, Lixun Huang 1, Yuying Yao 1, Liuyou Li 1, Jian Chen 1, Rongxin Zhang 1,2, Jia Zhou 3*, Lijing Wang 1,2* and Qian-Qian Zhang 1,2* 1 School of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, China, 2 Guangdong Province Key Laboratory for Biotechnology Drug Candidates, Guangdong Pharmaceutical University, Guangzhou, China, Edited by: 3 Chemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, 4 ’ fi Salvatore Salomone, TX, United States, Department of Pathology, People s Hospital of Baoan District, Af liated Baoan Hospital of Shenzhen, fi University of Catania, Italy Southern Medical University, The Second Af liated Hospital of Shenzhen University, Shenzhen, China Reviewed by: Gerald V. Denis, Angiogenesis dysregulation contributes to inflammation, infections, immune disorders, Boston University, United States and carcinogenesis. Bromodomain-containing protein 4 (BRD4) is an epigenetic reader Susanne Müller, Goethe University Frankfurt, that recognizes histone proteins and acts as a transcriptional regulator to trigger tumor Germany growth and the inflammatory response. The pan-bromodomain and extra-terminal *Correspondence: domain (BET) inhibitor, (+)-JQ1 (1), was reported to inhibit angiogenesis. However, Qian-Qian Zhang
[email protected] owing to the non-selectivity action of (+)-JQ1 towards all BET family members, the role Lijing Wang of BRD4 and that of its bromodomains (BD1 and BD2) in angiogenesis remains elusive.
[email protected] Herein, we identified a potent BRD4 inhibitor, ZL0513 (7), which exhibited significant anti- Jia Zhou
[email protected] angiogenic effects in chick embryo chorioallantoic membrane (CAM) and yolk sac †These authors have contributed membrane (YSM) models.